Fig. 4

EVI1 overexpression expands myelopoiesis. a Quantification of GFP−, CD11b+ myelocytes, either overexpressing EVI1 or WT as indicated in WBM of competitively transplanted recipients, harvested 2, 6, or 10 weeks after DOX induction. (WT n = 4 mice, EVI1 n = 4 mice at each time point, total n = 24). b Quantification of GFP− LY6G/C+ myelocytes, either overexpressing EVI1 or WT in WBM of competitively transplanted recipients harvested 2, 6, or 10 weeks after DOX induction. (WT n = 4 mice, EVI1 n = 4 mice at each time point, total n = 24). c Flow cytometry analysis of progenitor populations from recipient mice after 10 weeks of DOX treatment. Data represents mean number of cells per femur for individual mice. (WT n = 5, Evi1+ n = 4). d Relative numbers of GFP− CFC-myeloid (G−, M and GM-CFC) in bone marrow of competitively transplanted mice 10 weeks post induction, comparing the Evi1^TO/TO Rosa26^rtTA/rtTA:WT to WT:WT transplants as indicated. (WT n = 8, EVI1 n = 8). e Quantification of GFP− monocyte/macrophage (nucleated, CD11b+, Gr1−) or GFP− granulocytes (nucleated, CD11b+, Gr1+) as determined by imaging flow cytometry in bone marrow of competitively transplanted mice, comparing Evi1^TO/TO Rosa26^rtTA/rtTA donor cells to WT donor cells, 10 weeks post induction. (WT n = 8, EVI1 n = 8). f Quantification of GFP− apoptotic (annexin-V+ 7AAD−) CD11b+ myelocytes (left) and LY6G/C+ myelocytes (right), comparing WT to EVI1-overexpressing cells in WBM of competitively transplanted recipients harvested 10 weeks after DOX induction. Each dot represents an individual recipient mouse. (WT n = 8, EVI1 n = 8). For all panels, error bars represent standard deviation; p values calculated with Student’s t-test